Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Nephros (NEPH) over the last 17 years, with Q3 2025 value amounting to $13.2 million.

  • Nephros' Liabilities and Shareholders Equity rose 2754.67% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year increase of 829.93%. This contributed to the annual value of $11.2 million for FY2024, which is 548.86% down from last year.
  • As of Q3 2025, Nephros' Liabilities and Shareholders Equity stood at $13.2 million, which was up 2754.67% from $12.2 million recorded in Q2 2025.
  • Nephros' 5-year Liabilities and Shareholders Equity high stood at $18.0 million for Q2 2021, and its period low was $10.4 million during Q2 2023.
  • Over the past 5 years, Nephros' median Liabilities and Shareholders Equity value was $11.8 million (recorded in 2025), while the average stood at $13.1 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 3768.27% in 2022, then skyrocketed by 2754.67% in 2025.
  • Nephros' Liabilities and Shareholders Equity (Quarter) stood at $17.6 million in 2021, then crashed by 37.68% to $11.0 million in 2022, then increased by 7.84% to $11.9 million in 2023, then fell by 5.49% to $11.2 million in 2024, then increased by 18.17% to $13.2 million in 2025.
  • Its Liabilities and Shareholders Equity was $13.2 million in Q3 2025, compared to $12.2 million in Q2 2025 and $11.8 million in Q1 2025.